Therapeutic Potential of Iron Chelators in Viral Diseases: A Systematic Review

Author:

Lori Maryam Shamseddini1,Khandani Azade Kalantari1,Dehghannoudeh Gholamreza2,Ohadi Mandana2,Ansari Mehdi3

Affiliation:

1. Department of Pharmaceutics, Faculty of Pharmacy, Kerman Medical Science University, Kerman, Iran

2. Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

3. Department of Drug and Food Control, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Background: Iron chelators (ICs) have recently emerged as one of the new methods of treatment for viral infections. This study aimed to evaluate the efficiency and safety of natural ICs compared to synthetic ICs. Natural and synthetic ICs are the most common therapeutic agents tested for the treatment of viral infections. When evaluated against synthetic ICs, natural ICs are probably favored owing to their lower toxicity and safer properties. The main objective of the present systematic review was to assess the current evidence on the role of pharmacological mechanisms in the treatment of viral infections. Methods: This study was designed as a systematic review in which search strategies were focused on two electronic databases, PubMed, and Scopus, between 2017 and 2021. A search filter with two subjects, “iron chelators” and “viral infection”, was employed. Results: According to the results, both natural and synthetic chelators had a considerable impact on the treatment of viral infections via various mechanisms, with natural ICs being the most extensively used. Conclusion: Natural and synthetic ICs exert their effects through different pharmacological mechanisms. Among these compounds, natural chelators are more widely used due to their safety, efficacy, and a wider range of applications.

Publisher

Bentham Science Publishers Ltd.

Reference48 articles.

1. Mirza A.Z.; Shamshad H.; Osra F.A.; Habeebullah T.M.; Morad M.; An overview of viruses discovered over the last decades and drug development for the current pandemic. Eur J Pharmacol 2021,890,173746

2. Wu F.; Zhao S.; Yu B.; Chen Y.M.; Wang W.; Song Z.G.; Hu Y.; Tao Z.W.; Tian J.H.; Pei Y.Y.; Yuan M.L.; Zhang Y.L.; Dai F.H.; Liu Y.; Wang Q.M.; Zheng J.J.; Xu L.; Holmes E.C.; Zhang Y.Z.; A new coronavirus associated with human respiratory disease in China. Nature 2020,579(7798),265-269

3. WHO estimated that in 2019, approximately 290, 000 people died from hepatitis C 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=WHO%20estimated%20that%20in%202019%2C%20approximately%20290%20000,is%20currently%20no%20effective%20vaccine%20against%20hepatitis%20C2019

4. In 2019, hepatitis B resulted in an estimated 820, 000 deaths. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b2019

5. Schmidt S.M.; The role of iron in viral infections. Front Biosci 2020,25(4),893-911

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3